ADCT

ADC Therapeutics S.A. (ADCT) | Rumor.io

ADC Therapeutics

ADCT

Attention (50-day avg)0%

Attention rank (50-day avg)#3,204

Bullish sentiment (50-day avg)33%

Price to earnings ratio-1.11

Market capitalization160.9M

Earnings per share-0.58

Dividend yield (TTM)—

Revenue (annual)81.4M

Net income (annual)-142.6M

Social

What share of all stock conversation is about ADCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 8

The company's Phase 3 LOTIS-5 confirmatory trial delivered topline data, which may be an opportunity for a bounce back in the stock price.
The market is discounting the value of the company's pipeline and granting no value to its current product, with some analysts suggesting a market cap of around $120M.
The company's cancer drug Zynlonta has a well-established and effective profile, with a composition of matter patent that extends into 2035, and may be worth north of $5-6 per share.

Generated by AI

Sentiment

Of the messages about ADCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +80	74.53% -9.66
Bearish	—	—	0% -80	25.47% +9.66

Bullish· May 6

$ADCT is capitalized for Q2 with sales growth, with no negative clinical results to worry about, and potential for a partnership with new assets.
The company's private offering is beneficial for both the company and long-term investors, with no cash flow or interest rate concerns for the next two years.
$ADCT's Zynlonta product has a growing projected value, with potential peak sales of $500-800M, and the company is still in the early stages of its product life cycle.

Bearish· Jun 4

The LOTIS-5 trial showed a statistically significant improvement in progression-free survival, but with higher serious adverse events and Grade 5 events in the treatment arm.
The company has a history of failed compounds, including camidanlumab, AXL, and CD22, and has been criticized for its handling of the LOTIS-9 discontinuation and the rejection of its AA.
The company's balance sheet is "disgusting" and it is trading at 2x sales, indicating a potential undervaluation of the company's assets.

Generated by AI

Topics

Of the messages about ADCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	91.77%
Technical Analysis	—	—	—	4.11%
Earnings	—	—	—	2.31%
Controversies	—	—	—	0.26%
Analysts	—	—	—	1.54%
Macro	—	—	—	0%

Announcements· Dec 6

ADC Therapeutics will host a conference call on December 11, 2024, to discuss preliminary data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma.
The trial's early results show promising safety and efficacy of the combination therapy.
The conference call will be held on December 11, 2024, at 8:30 a.m. ET and will provide an update on the preliminary data from the LOTIS-7 Phase 1b open-label clinical trial.

Technical Analysis· Dec 22

$ADCT is forming a long-term downward wedge, potentially setting up for a breakout with a $8.50 price target.
The stock has a double bottom pattern with bullish hidden and 1hr divergences, as well as a recent bullish reversal candle on the daily chart.
The momentum indicator exceeded the 0 level on December 21, 2022, indicating that $ADCT has entered an uptrend.

Generated by AI

Community

Of the messages about ADCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	42.86%	66.55%
Newcomers	—	—	57.14%	33.45%

Regulars· May 6

ADC Therapeutics has announced an initial data from an investigator-initiated Phase 2 clinical trial of ZYNLONTA in patients with relapsed/refractory marginal zone lymphoma, showing promising results.
The company plans to raise $105 million through the sale of common shares and pre-funded warrants, with a price of $4.90 per share.
ADC Therapeutics has reported a Non-GAAP EPS of -$0.38 and revenue of $17.8 million in its Q1 2024 earnings call, missing estimates by $0.32 million.

Newcomers· Dec 6

The LOTIS-7 Phase 1b clinical trial data will be presented on December 11, 2024, providing an update on the safety and efficacy of the treatment.
The company is expected to release preliminary data from the LOTIS-7 trial, which could lead to a significant increase in the stock price.
The presentation of the LOTIS-7 data is considered a major data catalyst, with the potential to impact the stock price positively.

Generated by AI

News

ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

17d agoSeeking Alpha

ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test

19d agoInvesting.com

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

27d agoMorningstar

Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Generation ADC Pipeline to Clinic

29d agoYahoo Finance

ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses

On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […]

1mo agoYahoo Finance

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about ADCT also mention

#	Name	Attention
1	Sutro Biopharma Inc.STRO	0%new
2	Genmab A/S American Depositary SharesGMAB	0%0
3	MRTX - Mirati Therapeutics, Inc.	——
4	NARI - Inari Medical, Inc.	——
5	Bicycle Therapeutics plc - ADRBCYC	0%0
6	BioAtla Inc.BCAB	0%new
7	MRUS - Merus N.V.	——
8	BPMC - Blueprint Medicines Corporation	——
9	IGMS - IGM Biosciences, Inc.	——
10	ITOS - iTeos Therapeutics, Inc.	——

ADC Therapeutics S.A.

Healthcare
Drug Manufacturers - Specialty & Generic

ADC Therapeutics S.A. is a biotechnology company engaged in developing and commercializing antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. The primary goal of ADC Therapeutics is to address major unmet medical needs by harnessing the potency of targeted drug delivery. By combining the targeting capability of monoclonal antibodies with the cancer-killing effects of potent cytotoxic drugs, the company's ADCs aim to selectively attack cancer cells while minimizing damage to healthy tissues. ADC Therapeutics targets a range of malignancies, including non-Hodgkin lymphoma and other aggressive blood cancers, with a robust pipeline of therapeutics in various stages of clinical trials. Headquartered in Switzerland, the company plays a significant role in the biopharmaceutical industry, collaborating with other research entities and leveraging cutting-edge technology to advance cancer treatment. Its scientific innovation and potential breakthrough therapies contribute substantially to the evolving landscape of oncology medicine.

Website

Location

BiopOle

Epalinges, 1066

Switzerland

Social

What share of all stock conversation is about ADCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 8

The company's Phase 3 LOTIS-5 confirmatory trial delivered topline data, which may be an opportunity for a bounce back in the stock price.
The market is discounting the value of the company's pipeline and granting no value to its current product, with some analysts suggesting a market cap of around $120M.
The company's cancer drug Zynlonta has a well-established and effective profile, with a composition of matter patent that extends into 2035, and may be worth north of $5-6 per share.

Generated by AI

Sentiment

Of the messages about ADCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +80	74.53% -9.66
Bearish	—	—	0% -80	25.47% +9.66

Bullish· May 6

$ADCT is capitalized for Q2 with sales growth, with no negative clinical results to worry about, and potential for a partnership with new assets.
The company's private offering is beneficial for both the company and long-term investors, with no cash flow or interest rate concerns for the next two years.
$ADCT's Zynlonta product has a growing projected value, with potential peak sales of $500-800M, and the company is still in the early stages of its product life cycle.

Bearish· Jun 4

The LOTIS-5 trial showed a statistically significant improvement in progression-free survival, but with higher serious adverse events and Grade 5 events in the treatment arm.
The company has a history of failed compounds, including camidanlumab, AXL, and CD22, and has been criticized for its handling of the LOTIS-9 discontinuation and the rejection of its AA.
The company's balance sheet is "disgusting" and it is trading at 2x sales, indicating a potential undervaluation of the company's assets.

Generated by AI

Topics

Of the messages about ADCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	91.77%
Technical Analysis	—	—	—	4.11%
Earnings	—	—	—	2.31%
Controversies	—	—	—	0.26%
Analysts	—	—	—	1.54%
Macro	—	—	—	0%

Announcements· Dec 6

ADC Therapeutics will host a conference call on December 11, 2024, to discuss preliminary data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma.
The trial's early results show promising safety and efficacy of the combination therapy.
The conference call will be held on December 11, 2024, at 8:30 a.m. ET and will provide an update on the preliminary data from the LOTIS-7 Phase 1b open-label clinical trial.

Technical Analysis· Dec 22

$ADCT is forming a long-term downward wedge, potentially setting up for a breakout with a $8.50 price target.
The stock has a double bottom pattern with bullish hidden and 1hr divergences, as well as a recent bullish reversal candle on the daily chart.
The momentum indicator exceeded the 0 level on December 21, 2022, indicating that $ADCT has entered an uptrend.

Generated by AI

Community

Of the messages about ADCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	42.86%	66.55%
Newcomers	—	—	57.14%	33.45%

Regulars· May 6

ADC Therapeutics has announced an initial data from an investigator-initiated Phase 2 clinical trial of ZYNLONTA in patients with relapsed/refractory marginal zone lymphoma, showing promising results.
The company plans to raise $105 million through the sale of common shares and pre-funded warrants, with a price of $4.90 per share.
ADC Therapeutics has reported a Non-GAAP EPS of -$0.38 and revenue of $17.8 million in its Q1 2024 earnings call, missing estimates by $0.32 million.

Newcomers· Dec 6

The LOTIS-7 Phase 1b clinical trial data will be presented on December 11, 2024, providing an update on the safety and efficacy of the treatment.
The company is expected to release preliminary data from the LOTIS-7 trial, which could lead to a significant increase in the stock price.
The presentation of the LOTIS-7 data is considered a major data catalyst, with the potential to impact the stock price positively.

Generated by AI

ADC Therapeutics

Social

Jun 8

Bullish· May 6

Bearish· Jun 4

Announcements· Dec 6

Technical Analysis· Dec 22

Regulars· May 6

Newcomers· Dec 6

ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Generation ADC Pipeline to Clinic

ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

Also Discussed

ADC Therapeutics S.A.

Company Information

Location

ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Generation ADC Pipeline to Clinic

ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Jun 8

Bullish· May 6

Bearish· Jun 4

Announcements· Dec 6

Technical Analysis· Dec 22

Regulars· May 6

Newcomers· Dec 6